Subsequently, second-generation FLT3 TKIs, gilteritinib (Gil) and quizartinib (Quiz), were approved as monotherapies for relapsed or refractory AML in Japan [7,8,9,10]. Here, FLT3 is linked to acute myeloid leukemia.